Motley Fool14d agoneutral
Gilead Sciences Just Won Its Third FDA Approval in Less Than 4 Months. Is the Stock Still Underrating This Turnaround Play?Gilead Sciences is branching out beyond its HIV franchise into oncology and immunology therapies.
News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
68last 24h
974last 7d
109● bullish (7d)
123● bearish (7d)
212publishers